Alberto Martini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1264986/publications.pdf

Version: 2024-02-01

386 papers 33,278 citations

94 h-index 166 g-index

402 all docs

402 docs citations

402 times ranked 19954 citing authors

#	Article	IF	CITATIONS
1	Juvenile idiopathic arthritis. Lancet, The, 2007, 369, 767-778.	13.7	1,426
2	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Annals of the Rheumatic Diseases, 2010, 69, 798-806.	0.9	1,073
3	Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism, 1997, 40, 1202-1209.	6.7	922
4	Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, 2012, 71, 1771-1782.	0.9	868
5	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2385-2395.	27.0	716
6	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care and Research, 2011, 63, 465-482.	3.4	658
7	Juvenile idiopathic arthritis. Lancet, The, 2011, 377, 2138-2149.	13.7	638
8	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2396-2406.	27.0	588
9	Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis and Rheumatism, 2009, 61, 658-666.	6.7	579
10	Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2008, 359, 810-820.	27.0	530
11	Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet, The, 2008, 372, 383-391.	13.7	486
12	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	5 . 6	427
13	A randomized, placeboâ€controlled trial of infliximab plus methotrexate for the treatment of polyarticularâ€course juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 3096-3106.	6.7	373
14	Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Journal of Pediatrics, 2005, 146, 598-604.	1.8	365
15	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
16	The pattern of response to anti–interleukinâ€1 treatment distinguishes two subsets of patients with systemicâ€onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 58, 1505-1515.	6.7	346
17	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.9	338
18	Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. Journal of Experimental Medicine, 2005, 201, 1793-1803.	8.5	332

#	Article	IF	CITATIONS
19	Correlation of Serum Interleukinâ€6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rheumatoid Arthritis. Arthritis and Rheumatism, 1991, 34, 1158-1163.	6.7	325
20	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	5.6	322
21	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. Journal of Rheumatology, 2019, 46, 190-197.	2.0	318
22	A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis and Rheumatism, 2004, 50, 2191-2201.	6.7	307
23	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
24	Persistent efficacy of anakinra in patients with tumor necrosis factor receptor–associated periodic syndrome. Arthritis and Rheumatism, 2008, 58, 1516-1520.	6.7	297
25	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases, 2014, 73, 2160-2167.	0.9	256
26	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117.	0.9	251
27	Bone Marrow-Derived Mesenchymal Stem Cells Induce Both Polyclonal Expansion and Differentiation of B Cells Isolated from Healthy Donors and Systemic Lupus Erythematosus Patients. Stem Cells, 2008, 26, 562-569.	3.2	247
28	Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence. JAMA - Journal of the American Medical Association, 2016, 316, 1906.	7.4	242
29	Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirtyâ€eight patients. Arthritis and Rheumatism, 2009, 60, 3388-3399.	6.7	231
30	Pattern of interleukinâ \in 1 \hat{l}^2 secretion in response to lipopolysaccharide and ATP before and after interleukinâ \in 1 blockade in patients with <i>ClAS1</i> mutations. Arthritis and Rheumatism, 2007, 56, 3138-3148.	6.7	229
31	Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission <subtitle>A Randomized Clinical Trial</subtitle> . JAMA - Journal of the American Medical Association, 2010, 303, 1266.	7.4	229
32	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
33	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. British Journal of Rheumatology, 2003, 42, 1452-1459.	2.3	209
34	Longâ€ŧerm outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care and Research, 2010, 62, 63-72.	3.4	207
35	Longâ€term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2010, 62, 1792-1802.	6.7	204
36	ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Annals of the Rheumatic Diseases, 2017, 76, 1648-1656.	0.9	199

3

#	Article	IF	Citations
37	Patients with antinuclear antibody–positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis and Rheumatism, 2005, 52, 826-832.	6.7	197
38	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. Pediatrics, 2008, 122, e1100-e1107.	2.1	193
39	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 2010, 69, 790-797.	0.9	187
40	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.9	180
41	Functional and prognostic relevance of the â^'173 polymorphism of the macrophage migration inhibitory factor gene in systemicâ€onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 1398-1407.	6.7	173
42	Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis and Rheumatism, 2012, 64, 2366-2374.	6.7	171
43	Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature Medicine, 1995, 1, 448-452.	30.7	168
44	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	5.6	168
45	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, The, 2016, 387, 671-678.	13.7	168
46	A phase II, multicenter, openâ€label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and Rheumatism, 2012, 64, 557-567.	6.7	167
47	Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis and Rheumatism, 2011, 63, 830-839.	6.7	162
48	Interferonâ€Î³â€"dependent inhibition of B cell activation by bone marrow–derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 2776-2786.	6.7	161
49	A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report. Journal of Rheumatology, 2011, 38, 938-953.	2.0	159
50	An International registry on Autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases, 2012, 71, 1177-1182.	0.9	158
51	EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Annals of the Rheumatic Diseases, 2017, 76, 639-646.	0.9	157
52	It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Annals of the Rheumatic Diseases, 2012, 71, 1437-1439.	0.9	154
53	Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis and Rheumatism, 2003, 49, 501-507.	6.7	150
54	Effect of IL-6 on IGF Binding Protein-3: A Study in IL-6 Transgenic Mice and in Patients with Systemic Juvenile Idiopathic Arthritis. Endocrinology, 2001, 142, 4818-4826.	2.8	147

#	Article	IF	Citations
55	Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Archives of Disease in Childhood, 2011, 96, 596-601.	1.9	143
56	Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2005, 52, 2092-2102.	6.7	142
57	Successful treatment of idiopathic recurrent pericarditis in children with interleukinâ€1β receptor antagonist (anakinra): An unrecognized autoinflammatory disease?. Arthritis and Rheumatism, 2009, 60, 264-268.	6.7	142
58	An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2011, 38, 764-768.	2.0	140
59	Antinuclear antibody–positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis and Rheumatism, 2011, 63, 267-275.	6.7	140
60	<i>HLA-DRB1*11</i> i>and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	7.1	139
61	Neutrophils from patients withTNFRSF1A mutations display resistance to tumor necrosis factor–induced apoptosis: Pathogenetic and clinical implications. Arthritis and Rheumatism, 2006, 54, 998-1008.	6.7	138
62	Differentiating PFAPA Syndrome From Monogenic Periodic Fevers. Pediatrics, 2009, 124, e721-e728.	2.1	138
63	The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/european League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study. Arthritis and Rheumatism, 2008, 59, 4-13.	6.7	136
64	Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. Journal of Pediatrics, 1996, 128, 275-278.	1.8	134
65	A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 2989-2996.	6.7	133
66	Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL- $1\hat{1}^2$ secretion. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9789-9794.	7.1	129
67	Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Annals of the Rheumatic Diseases, 2010, 69, 718-722.	0.9	129
68	Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 59, 1764-1772.	6.7	126
69	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.9	123
70	Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study. Arthritis and Rheumatism, 2007, 57, 35-43.	6.7	121
71	Macrophage Activation Syndrome. Hematology/Oncology Clinics of North America, 2015, 29, 927-941.	2.2	121
72	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases, 2014, 73, 2168-2173.	0.9	120

#	Article	IF	Citations
73	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	5.6	120
74	Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2010, 37, 1534-1541.	2.0	119
75	Systemic juvenile idiopathic arthritis. Autoimmunity Reviews, 2012, 12, 56-59.	5.8	118
76	Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Threeâ€Variable Juvenile Arthritis Disease Activity Score. Arthritis Care and Research, 2014, 66, 1703-1709.	3.4	115
77	Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2014, 73, 1083-1090.	0.9	113
78	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo. Journal of the American Society of Nephrology: JASN, 2014, 25, 2483-2498.	6.1	112
79	EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice. Annals of the Rheumatic Diseases, 2015, 74, 1946-1957.	0.9	112
80	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2013, 72, 686-693.	0.9	109
81	Increased NLRP3-dependent interleukin $1\hat{l}^2$ secretion in patients with familial Mediterranean fever: correlation with < i > MEFV < / i > genotype. Annals of the Rheumatic Diseases, 2014, 73, 462-469.	0.9	108
82	Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Annals of the Rheumatic Diseases, 2014, 73, 1114-1122.	0.9	106
83	Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2835-2840.	7.1	106
84	Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 2020, 79, 1340-1348.	0.9	106
85	Follow-Up and Quality of Life of Patients with Cryopyrin-Associated Periodic Syndromes Treated with Anakinra. Journal of Pediatrics, 2010, 157, 310-315.e1.	1.8	105
86	Role of IL-1 Beta in the Development of Human TH17 Cells: Lesson from NLPR3 Mutated Patients. PLoS ONE, 2011, 6, e20014.	2.5	105
87	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology, 2018, 57, 1203-1211.	1.9	105
88	Nephroticâ€range proteinuria, the major risk factor for early atherosclerosis in juvenileâ€onset systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 1405-1409.	6.7	103
89	Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Annals of the Rheumatic Diseases, 2012, 71, 1991-1997.	0.9	103
90	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis and Rheumatology, 2016, 68, 218-228.	5.6	103

#	Article	IF	CITATIONS
91	Juvenile idiopathic arthritis: state of the art and future perspectives. Annals of the Rheumatic Diseases, 2010, 69, 1260-1263.	0.9	101
92	Paediatric-onset systemic lupus erythematosus. Best Practice and Research in Clinical Rheumatology, 2013, 27, 351-362.	3.3	101
93	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 2871-2880.	5.6	101
94	Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatric Rheumatology, 2015, 13, 50.	2.1	100
95	Longâ€term clinical profile of children with the lowâ€penetrance R92Q mutation of the <i>TNFRSF1A</i> gene. Arthritis and Rheumatism, 2011, 63, 1141-1150.	6.7	99
96	Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 59, 1120-1127.	6.7	98
97	Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatric Radiology, 2010, 40, 985-998.	2.0	97
98	Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Annals of the Rheumatic Diseases, 2017, 76, 173-178.	0.9	96
99	Leak Detection in Water-Filled Small-Diameter Polyethylene Pipes by Means of Acoustic Emission Measurements. Applied Sciences (Switzerland), 2017, 7, 2.	2.5	96
100	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the Rheumatic Diseases, 2018, 77, 21-29.	0.9	96
101	Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 57, 913-920.	6.7	95
102	Long-Term Efficacy of Interleukin-1 Receptor Antagonist (Anakinra) in Corticosteroid-Dependent and Colchicine-Resistant Recurrent Pericarditis. Journal of Pediatrics, 2014, 164, 1425-1431.e1.	1.8	94
103	Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 3509-3517.	6.7	93
104	Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis and Rheumatism, 2004, 51, 458-464.	6.7	93
105	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Annals of the Rheumatic Diseases, 2014, 73, 662-667.	0.9	92
106	Diagnosis and Management of Autoinflammatory Diseases in Childhood. Journal of Clinical Immunology, 2008, 28, 73-83.	3.8	90
107	Juvenile idiopathic arthritis. Nature Reviews Disease Primers, 2022, 8, 5.	30.5	90
108	International research networks in pediatric rheumatology: the PRINTO perspective. Current Opinion in Rheumatology, 2004, 16, 566-570.	4.3	87

#	Article	IF	Citations
109	Development and internal validation of a sideâ€specific, multiparametric magnetic resonance imagingâ€based nomogram for the prediction of extracapsular extension of prostate cancer. BJU International, 2018, 122, 1025-1033.	2.5	86
110	Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis). Pediatric Rheumatology, 2014, 12, 18.	2.1	85
111	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	3.4	84
112	Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 56, 3087-3095.	6.7	80
113	A randomized, doubleâ€blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Short―and longâ€ŧerm efficacy and safety results. Arthritis and Rheumatism, 2005, 52, 563-572.	6.7	79
114	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the Rheumatic Diseases, 2018, 77, 1710-1719.	0.9	79
115	Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet, The, 2021, 398, 1984-1996.	13.7	79
116	Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy. European Urology, 2020, 78, 583-591.	1.9	78
117	Outcome in juvenile onset systemic lupus erythematosus. Current Opinion in Rheumatology, 2005, 17, 568-573.	4.3	77
118	The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. Arthritis and Rheumatism, 2005, 52, 2854-2864.	6.7	77
119	Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. Annals of the Rheumatic Diseases, 2014, 73, 1380-1383.	0.9	77
120	Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis?. Journal of Rheumatology, 2003, 30, 1900-3.	2.0	77
121	<i>EXTL3</i> mutations cause skeletal dysplasia, immune deficiency, and developmental delay. Journal of Experimental Medicine, 2017, 214, 623-637.	8.5	76
122	A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy. European Urology, 2018, 74, 833-839.	1.9	76
123	Activity of Classical and Alternative Pathways of Complement in Preterm and Small for Gestational Age Infants. Pediatric Research, 1984, 18, 281-285.	2.3	7 5
124	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatology International, 2018, 38, 5-17.	3.0	74
125	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1357-1362.	0.9	74
126	The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement. Arthritis and Rheumatism, 2006, 55, 355-363.	6.7	72

#	Article	IF	Citations
127	Abatacept improves healthâ€related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care and Research, 2010, 62, 1542-1551.	3.4	72
128	Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2012, 39, 856-863.	2.0	72
129	Dependence of Immunoglobulin Class Switch Recombination in B Cells on Vesicular Release of ATP and CD73 Ectonucleotidase Activity. Cell Reports, 2013, 3, 1824-1831.	6.4	72
130	The natural history of untreated muscleâ€invasive bladder cancer. BJU International, 2020, 125, 270-275.	2.5	72
131	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 807-811.	6.7	71
132	MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. European Journal of Human Genetics, 2005, 13, 314-320.	2.8	71
133	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Research and Therapy, 2018, 20, 285.	3.5	71
134	Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2006, 55, 177-183.	6.7	70
135	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Annals of the Rheumatic Diseases, 2011, 70, 309-314.	0.9	70
136	Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. Pediatric Rheumatology, 2012, 10, 39.	2.1	70
137	Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. Rheumatology, 2010, 49, 178-185.	1.9	69
138	Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 72, 1044-1052.	0.9	69
139	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
140	Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 232-237.	6.7	67
141	Differential recognition of heat-shock protein dnaJ–derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 56, 1648-1657.	6.7	67
142	Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 2721-2729.	6.7	66
143	Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the <i>Rag2</i> mouse model of Omenn syndrome. Journal of Experimental Medicine, 2010, 207, 1525-1540.	8.5	66
144	Clinical impact of <i>MEFV </i> mutations in children with periodic fever in a prevalent western European Caucasian population. Annals of the Rheumatic Diseases, 2012, 71, 1961-1965.	0.9	65

#	Article	IF	Citations
145	The Immune Inhibitory Receptor LAIR-1 Is Highly Expressed by Plasmacytoid Dendritic Cells and Acts Complementary with NKp44 to Control IFN1± Production. PLoS ONE, 2010, 5, e15080.	2.5	64
146	Long‶erm Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years. Arthritis and Rheumatology, 2015, 67, 2759-2770.	5.6	64
147	TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis. Annals of the Rheumatic Diseases, 2017, 76, 435-441.	0.9	64
148	Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatric Rheumatology, 2017, 15, 86.	2.1	64
149	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. Autoimmunity Reviews, 2015, 14, 692-702.	5.8	63
150	Catchâ€Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial. Arthritis and Rheumatology, 2015, 67, 840-848.	5.6	63
151	A circulating reservoir of pathogenic-like CD4 ⁺ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment. Annals of the Rheumatic Diseases, 2016, 75, 459-465.	0.9	62
152	Use of the sharp and larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2006, 55, 717-723.	6.7	61
153	Achievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 628-634.	2.0	61
154	Recurrent pericarditis in children and adolescents. Journal of Cardiovascular Medicine, 2016, 17, 707-712.	1.5	61
155	Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 440-446.	0.9	60
156	Targeting the interleukinâ€6 receptor: A new treatment for systemic juvenile idiopathic arthritis?. Arthritis and Rheumatism, 2005, 52, 687-693.	6.7	59
157	Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 1627-1634.	1.9	59
158	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 994-1001.	2.0	59
159	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative, Arthritis and Rheumatology, 2017, 69, 911-923.	5.6	59
160	Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. Journal of Pediatrics, 1998, 133, 262-265.	1.8	58
161	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2). Journal of the American Society of Nephrology: JASN, 2015, 26, 1905-1924.	6.1	58
162	The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. Journal of Pediatrics, 1999, 135, 316-320.	1.8	57

#	Article	IF	CITATIONS
163	Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs. Arthritis and Rheumatism, 2010, 62, 3131-3139.	6.7	57
164	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	3.8	57
165	Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases. Annals of the Rheumatic Diseases, 2016, 75, 1550-1557.	0.9	57
166	Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Research, 2004, 7, R256.	2.0	56
167	Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI: SDI). Arthritis Care and	3.4	55
168	Research, 2011, 63, S112-7. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, 511-517.	0.9	55
169	Autocorrelation Analysis of Vibro-Acoustic Signals Measured in a Test Field for Water Leak Detection. Applied Sciences (Switzerland), 2018, 8, 2450.	2.5	55
170	Methotrexate Therapy May Prevent the Onset of Uveitis in Juvenile Idiopathic Arthritis. Journal of Pediatrics, 2013, 163, 879-884.	1.8	54
171	Anakinra. Journal of Cardiovascular Medicine, 2016, 17, 256-262.	1.5	54
172	Automatic Leak Detection in Buried Plastic Pipes of Water Supply Networks by Means of Vibration Measurements. Shock and Vibration, 2015, 2015, 1-13.	0.6	53
173	Assessing current outcomes of juvenile idiopathic arthritis: A crossâ€sectional study in a tertiary center sample. Arthritis and Rheumatism, 2008, 59, 1571-1579.	6.7	52
174	The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Research and Therapy, 2013, 15, R33.	3.5	52
175	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. Journal of Rheumatology, 2016, 43, 154-160.	2.0	52
176	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet, The, 2017, 389, 909-916.	13.7	52
177	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2017, 69, 677-686.	3.4	52
178	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	2.7	52
179	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	8.0	52
180	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	1.8	50

#	Article	IF	Citations
181	Treatment of Takayasu's Arteritis with Tumor Necrosis Factor Antagonists. Journal of Pediatrics, 2008, 153, 432-434.	1.8	49
182	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Research and Therapy, 2017, 19, 13.	3.5	49
183	The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases. Frontiers in Immunology, 2013, 4, 351.	4.8	48
184	Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome. Rheumatology, 2016, 55, 1325-1335.	1.9	48
185	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Internal and Emergency Medicine, 2018, 13, 475-489.	2.0	48
186	Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. Internal and Emergency Medicine, 2018, 13, 839-844.	2.0	48
187	Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: An international multicenter PRINTO study. Arthritis and Rheumatism, 2011, 63, 3142-3152.	6.7	47
188	Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 949-955.	3.4	47
189	Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Annals of the Rheumatic Diseases, 2010, 69, 1479-1483.	0.9	46
190	Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. Journal of Rheumatology, 2016, 43, 816-824.	2.0	46
191	Vibroacoustic Measurements for Detecting Water Leaks in Buried Small-Diameter Plastic Pipes. Journal of Pipeline Systems Engineering and Practice, 2017, 8, .	1.6	46
192	Healthâ€related quality of life of patients with juvenile dermatomyositis: Results from the paediatric rheumatology international trials organisation multinational quality of life cohort study. Arthritis and Rheumatism, 2009, 61, 509-517.	6.7	45
193	Deficient production of IL-1 receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes. Annals of the Rheumatic Diseases, 2012, 71, 1577-1581.	0.9	45
194	Subcutaneous Abatacept in Patients With Polyarticularâ€Course Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1144-1154.	5.6	45
195	Cytokines in juvenile rheumatoid arthritis. Current Opinion in Rheumatology, 1997, 9, 428-433.	4.3	44
196	Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. Arthritis and Rheumatism, 2006, 55, 843-849.	6.7	44
197	Consensus procedures and their role in pediatric rheumatology. Current Rheumatology Reports, 2008, 10, 142-146.	4.7	44
198	Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis. Arthritis Research and Therapy, 2009, 11, R150.	3.5	44

#	Article	IF	CITATIONS
199	Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study. Arthritis and Rheumatology, 2019, 71, 1000-1010.	5.6	44
200	Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept. Journal of Rheumatology, 2013, 40, 192-200.	2.0	43
201	RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin- $1\hat{l}$ and interleukin- $1\hat{l}^2$ trap, in patients with recurrent pericarditis. American Heart Journal, 2020, 228, 81-90.	2.7	43
202	Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism, 1997, 40, 1202-1209.	6.7	40
203	Development and Testing of Reduced Joint Counts in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 183-190.	2.0	40
204	<i>IL1RN</i> Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukinâ€1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1319-1330.	5.6	40
205	A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. Rheumatology, 2010, 49, 1272-1280.	1.9	39
206	Advances from clinical trials in juvenile idiopathic arthritis. Nature Reviews Rheumatology, 2013, 9, 557-563.	8.0	39
207	Current and future perspectives in the management of juvenile idiopathic arthritis. The Lancet Child and Adolescent Health, 2018, 2, 360-370.	5.6	39
208	HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 966-972.	1.9	38
209	Delineating the Role of Multiple Intraarticular Corticosteroid Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era. Arthritis Care and Research, 2013, 65, 1112-1120.	3.4	38
210	Review: Beyond the NLRP3 Inflammasome: Autoinflammatory Diseases Reach Adolescence. Arthritis and Rheumatism, 2013, 65, 1137-1147.	6.7	37
211	Advances in biomarkers for paediatric rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 265-275.	8.0	37
212	Periodic fever, apthous stomatitis, pharyngitis and adenitis syndrome. Current Opinion in Rheumatology, 2010, 22, 579-584.	4.3	36
213	MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2013, 72, 363-368.	0.9	36
214	Hypoxic synovial environment and expression of macrophage inflammatory protein $3\hat{l}^3$ /CCL20 in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 58, 1833-1838.	6.7	35
215	Development and Initial Validation of a Radiographic Scoring System for the Hip in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2010, 37, 432-439.	2.0	35
216	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatric Rheumatology, 2016, 14, 68.	2.1	35

#	Article	IF	CITATIONS
217	A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2008, 67, 1159-1164.	0.9	34
218	Static balancing of a parallel kinematics machine with Linear-Delta architecture: theory, design and numerical investigation. Mechanism and Machine Theory, 2015, 90, 128-141.	4.5	34
219	Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. BJU International, 2019, 124, 665-671.	2.5	34
220	Algorithm for the static balancing of serial and parallel mechanisms combining counterweights and springs: Generation, assessment and ranking of effective design variants. Mechanism and Machine Theory, 2019, 137, 336-354.	4.5	34
221	Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clinical and Experimental Rheumatology, 2011, 29, 117-24.	0.8	34
222	Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2012, 30, S157-62.	0.8	34
223	Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 59, 1112-1119.	6.7	33
224	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteriaâ€"methodological aspects. Rheumatology, 2017, 56, 1884-1893.	1.9	33
225	Antiphospholipid Syndrome in Pediatrics. Rheumatic Disease Clinics of North America, 2007, 33, 499-523.	1.9	32
226	MRI of the wrist in juvenile idiopathic arthritis: proposal of a paediatric synovitis score by a consensus of an international working group. Results of a multicentre reliability study. Pediatric Radiology, 2012, 42, 1047-1055.	2.0	32
227	Diagnostic potential of hepcidin testing in pediatrics. European Journal of Haematology, 2013, 90, 323-330.	2.2	32
228	Juvenile idiopathic arthritis and malignancy. Rheumatology, 2014, 53, 968-974.	1.9	32
229	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscleâ€invasive bladder cancer. Cancer, 2019, 125, 3155-3163.	4.1	32
230	The Hypoxic Synovial Environment Regulates Expression of Vascular Endothelial Growth Factor and Osteopontin in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 1318-1329.	2.0	31
231	Clinical Characteristics of Patients Carrying the Q703K Variant of the <i>NLRP3</i> Gene: A 10-year Multicentric National Study. Journal of Rheumatology, 2016, 43, 1093-1100.	2.0	31
232	How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmunity Reviews, 2017, 16, 1008-1015.	5.8	31
233	CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever. Frontiers in Immunology, 2017, 8, 2015.	4.8	31
234	Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Research and Therapy, 2019, 21, 125.	3.5	31

#	Article	IF	CITATIONS
235	Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. Journal of Rheumatology, 2007, 34, 1773-6.	2.0	30
236	Systemic lupus erythematosus with jaccoud's arthropathy mimicking juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1987, 30, 1062-1064.	6.7	29
237	Impact of the European paediatric legislation in paediatric rheumatology: past, present and future. Annals of the Rheumatic Diseases, 2013, 72, 1893-1896.	0.9	29
238	Osteolytic Lesion in PAPA Syndrome Responding to Anti-interleukin 1 Treatment. Journal of Rheumatology, 2014, 41, 2333-2334.	2.0	28
239	Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization. Journal of Rheumatology, 2017, 44, 1667-1673.	2.0	28
240	Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. Journal of Rheumatology, 2005, 32, 1805-10.	2.0	28
241	The Clinical Significance of Antiphospholipid Antibodies. Annals of Medicine, 1997, 29, 159-163.	3.8	27
242	Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. Arthritis and Rheumatism, 2003, 49, 488-493.	6.7	27
243	Development and initial validation of composite parent―and childâ€centered disease assessment indices for juvenile idiopathic arthritis. Arthritis Care and Research, 2011, 63, 1262-1270.	3.4	27
244	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
245	Female Sex and Oligoarthritis Category Are Not Risk Factors for Uveitis in Italian Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 1416-1425.	2.0	25
246	The Extended Polydimensional Immunome Characterization (EPIC) web-based reference and discovery tool for cytometry data. Nature Biotechnology, 2020, 38, 679-684.	17.5	25
247	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Research and Therapy, 2020, 22, 71.	3.5	25
248	Criteria to define response to therapy in paediatric rheumatic diseases. European Journal of Clinical Pharmacology, 2011, 67, 125-131.	1.9	24
249	Predicting acute kidney injury after robot-assisted partial nephrectomy: Implications for patient selection and postoperative management. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 445-451.	1.6	24
250	Elastodynamic behavior of balanced closed-loop mechanisms: numerical analysis of a four-bar linkage. Meccanica, 2014, 49, 601-614.	2.0	23
251	Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 401-406.	0.9	23
252	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Openâ€Label, Randomized Study. Arthritis and Rheumatology, 2021, 73, 336-346.	5.6	23

#	Article	IF	CITATIONS
253	Clinical assessment in juvenile dermatomyositis. Autoimmunity, 2006, 39, 197-203.	2.6	22
254	HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatric Pulmonology, 2009, 44, 1226-1234.	2.0	22
255	Emerging drugs to treat juvenile idiopathic arthritis. Expert Opinion on Emerging Drugs, 2011, 16, 493-505.	2.4	22
256	Delineating the Application of Ultrasound in Detecting Synovial Abnormalities of the Subtalar Joint in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2016, 68, 1346-1353.	3. 4	22
257	Kawasaki disease or Kawasaki syndrome?. Annals of the Rheumatic Diseases, 2020, 79, 993-995.	0.9	22
258	Asymmetric Marfan syndrome. American Journal of Medical Genetics Part A, 1988, 30, 905-909.	2.4	21
259	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA). Pediatric Rheumatology, 2018, 16, 27.	2.1	21
260	An updated approach to incremental nerve sparing for robotâ€assisted radical prostatectomy. BJU International, 2019, 124, 103-108.	2. 5	21
261	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Openâ€Label, Activeâ€Treatment Extension Study. Arthritis and Rheumatology, 2020, 72, 2147-2158.	5 . 6	21
262	Gravity compensation of a 6-UPS parallel kinematics machine tool through elastically balanced constant-force generators. FME Transactions, 2018, 46, 10-16.	1.4	21
263	The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatric Rheumatology, 2010, 8, 24.	2.1	20
264	Current Medical Treatments for Juvenile Idiopathic Arthritis. Frontiers in Pharmacology, 2011, 2, 60.	3. 5	20
265	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. Arthritis Care and Research, 2018, 70, 1312-1319.	3.4	19
266	Static stress analysis of suspension systems for a solar-powered car. FME Transactions, 2019, 47, 70-75.	1.4	19
267	Pharmacologic P2X purinergic receptor antagonism in the treatment of collagenâ€induced arthritis. Arthritis and Rheumatism, 2011, 63, 3323-3332.	6.7	18
268	Murine <i>Ranklâ^'/â^'</i> Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector. Stem Cells, 2017, 35, 1365-1377.	3.2	18
269	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology, 2021, 60, 4568-4580.	1.9	18
270	Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene. Journal of Rheumatology, 2011, 38, 1378-1384.	2.0	17

#	Article	lF	CITATIONS
271	JIA, treatment and possible risk of malignancies. Nature Reviews Rheumatology, 2011, 7, 6-7.	8.0	17
272	Recurrent Pericarditis in Myhre Syndrome. American Journal of Medical Genetics, Part A, 2013, 161, 1164-1166.	1.2	17
273	Heading Toward a Modern Imaging Approach in Juvenile Idiopathic Arthritis. Current Rheumatology Reports, 2014, 16, 416.	4.7	17
274	Long-term complications arising from bowel interposition in the urinary tract. International Journal of Surgery, 2017, 44, 278-280.	2.7	17
275	The role of imaging in juvenile idiopathic arthritis. Expert Review of Clinical Immunology, 2018, 14, 681-694.	3.0	17
276	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Sevenâ€Year Interim Results. Arthritis Care and Research, 2020, 72, 1420-1430.	3.4	17
277	Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 470-472.	0.9	16
278	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
279	Efficacy and Safety of Tocilizumab for Polyarticularâ€Course Juvenile Idiopathic Arthritis in the Open‣abel Twoâ€Year Extension of a Phase III Trial. Arthritis and Rheumatology, 2021, 73, 530-541.	5.6	16
280	A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians. Italian Journal of Pediatrics, 2011, 37, 48.	2.6	15
281	Novel automated system for magnetic resonance imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. Arthritis Care and Research, 2012, 64, 1657-1664.	3.4	15
282	Elastodynamic Effects of Mass-Balancing: Experimental Investigation of a Four-Bar Linkage. Advances in Mechanical Engineering, 2013, 5, 949457.	1.6	15
283	Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study. Rheumatology, 2018, 57, 1752-1760.	1.9	15
284	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	1.9	15
285	Experimental Characterization of a High-Damping Viscoelastic Material Enclosed in Carbon Fiber Reinforced Polymer Components. Applied Sciences (Switzerland), 2020, 10, 6193.	2.5	15
286	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatric Rheumatology, 2020, 18, 19.	2.1	15
287	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology, 2021, 60, 4495-4507.	1.9	15
288	The obesity paradox in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 472-478.	3.9	15

#	Article	lF	Citations
289	Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Annals of Paediatric Rheumatology, 2012, 1, 1.	0.0	15
290	Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases. Archives of Disease in Childhood, 2012, 97, 561-563.	1.9	14
291	Patient's experiences with the care for juvenile idiopathic arthritis across Europe. Pediatric Rheumatology, 2018, 16, 10.	2.1	14
292	The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. Pediatric Rheumatology, 2019, 17, 24.	2.1	14
293	A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors. Journal of Allergy and Clinical Immunology, 2020, 145, 368-378.e13.	2.9	14
294	Strain Modal Testing with Fiber Bragg Gratings for Automotive Applications. Sensors, 2022, 22, 946.	3.8	14
295	The 423Q polymorphism of the Xâ€linked inhibitor of apoptosis gene influences monocyte function and is associated with periodic fever. Arthritis and Rheumatism, 2009, 60, 3476-3484.	6.7	13
296	Glucocorticoids in Juvenile Idiopathic Arthritis. NeuroImmunoModulation, 2015, 22, 112-118.	1.8	13
297	Upgrade of an automated line for plastic cap manufacture based on experimental vibration analysis. Case Studies in Mechanical Systems and Signal Processing, 2016, 3, 28-33.	1.4	13
298	Kinematics optimization of the polishing process of large-sized ceramic slabs. International Journal of Advanced Manufacturing Technology, 2019, 103, 1325-1336.	3.0	13
299	Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Annals of the Rheumatic Diseases, 2019, 78, 162-170.	0.9	13
300	Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open, 2020, 6, e001208.	3.8	13
301	Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Paediatric Drugs, 2020, 22, 653-672.	3.1	13
302	Virtual Testing of Counterbalance Forklift Trucks: Implementation and Experimental Validation of a Numerical Multibody Model. Machines, 2020, 8, 26.	2.2	13
303	STRUCTURAL AND ELASTODYNAMIC ANALYSIS OF ROTARY TRANSFER MACHINES BY FINITE ELEMENT MODEL. Journal of the Serbian Society for Computational Mechanics, 2017, 11, 1-16.	0.4	13
304	Treatment of autoinflammatory syndromes. Current Opinion in Pediatrics, 2010, 22, 771-778.	2.0	12
305	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Annals of the Rheumatic Diseases, 2013, 72, 1503-1509.	0.9	12
306	Are there new targets for juvenile idiopathic arthritis?. Seminars in Arthritis and Rheumatism, 2019, 49, S11-S13.	3.4	12

#	Article	IF	Citations
307	Successful treatment of subacute constrictive pericarditis with interleukin- $1\hat{l}^2$ receptor antagonist (anakinra). Clinical and Experimental Rheumatology, 2015, 33, 294-5.	0.8	12
308	Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index?. Annals of the Rheumatic Diseases, 2010, 69, 82-87.	0.9	11
309	A Metaâ€Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2016, 68, 1540-1550.	5.6	11
310	Molecular mechanisms of autophagic memory in pathogenic T cells in human arthritis. Journal of Autoimmunity, 2018, 94, 90-98.	6.5	11
311	An Approach for Predicting the Specific Fuel Consumption of Dual-Fuel Two-Stroke Marine Engines. Journal of Marine Science and Engineering, 2019, 7, 20.	2.6	11
312	Defining Risk Categories for a Significant Decline in Estimated Glomerular Filtration Rate After Robotic Partial Nephrectomy: Implications for Patient Follow-up. European Urology Oncology, 2021, 4, 498-501.	5.4	11
313	Extrapolation or controlled trials in paediatrics: the current dilemma. Archives of Disease in Childhood, 2017, 102, 949-951.	1.9	10
314	Educational initiatives and training for paediatric rheumatology in Europe. Pediatric Rheumatology, 2018, 16, 77.	2.1	10
315	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology, 2019, 58, 1196-1205.	1.9	10
316	How to Select the Optimal Candidates for Renal Mass Biopsy. European Urology Oncology, 2021, 4, 506-509.	5.4	10
317	Frequency of Radiographic Damage and Progression in Individual Joints in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 27-33.	3.4	9
318	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.9	9
319	Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. Prostate Cancer and Prostatic Diseases, 2020, 23, 638-645.	3.9	9
320	New takes on categorization and treatment. Nature Reviews Rheumatology, 2012, 8, 67-68.	8.0	8
321	Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 684.e9-684.e15.	1.6	8
322	Glucocorticoids in juvenile idiopathic arthritis. Annals of the New York Academy of Sciences, 2014, 1318, 65-70.	3.8	7
323	A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome. BJU International, 2019, 124, 155-162.	2.5	7
324	Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. Arthritis Care and Research, 2020, 72, 265-273.	3.4	7

#	Article	IF	Citations
325	Macrophage activation syndrome. Indian Journal of Rheumatology, 2012, 7, 27-35.	0.4	6
326	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12 , .	2.1	6
327	Conservative Treatment of Serous Borderline Paratesticular Tumor in a Pediatric Patient. Urology, 2016, 89, 123-125.	1.0	6
328	Preface. Rheumatology International, 2018, 38, 1-3.	3.0	6
329	Conditionally Reprogrammed Patient-derived Cells: A Step Forward Towards Personalized Medicine?. European Urology, 2019, 76, 435-436.	1.9	6
330	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. Clinical Genitourinary Cancer, 2019, 17, e541-e548.	1.9	6
331	Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. Urologic Oncology: Seminars and Original Investigations, 2021	1.6	6
332	Adjuvant immunotherapy in patients with highâ€risk muscleâ€invasive urothelial carcinoma: The potential impact of informative censoring. Cancer, 2022, 128, 2892-2897.	4.1	6
333	Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization. World Journal of Pediatrics, 2008, 4, 186-191.	1.8	5
334	Primary red ear syndrome associated with cochleo-vestibular symptomatology: A paediatric case report. Cephalalgia, 2013, 33, 1277-1280.	3.9	5
335	A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S67-S68.	5.6	5
336	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S23-S24.	5.6	5
337	Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients. Microorganisms, 2020, 8, 1540.	3.6	5
338	New autoantibodies and their clinical associations in juvenile myositis - a systematic review. Acta Reumatol \tilde{A}^3 gica Portuguesa, 2013, 38, 234-41.	0.2	5
339	A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study. Arthritis and Rheumatology, 2014, 66, S80-S81.	5.6	4
340	Effect of the Inclusion of the Metacarpophalangeal Joints on the Wrist Magnetic Resonance Imaging Scoring System in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2018, 45, 1581-1587.	2.0	4
341	Functional Ability and Healthâ€Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2020, 73, 1264-1274.	3.4	4
342	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. Prostate Cancer and Prostatic Diseases, 2021, 24, 743-749.	3.9	4

#	Article	IF	CITATIONS
343	Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman. Arthritis and Rheumatism, 2008, 58, 1201-1202.	6.7	3
344	Agreement Among Musculoskeletal Pediatric Specialists in the Assessment of Radiographic Joint Damage in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 34-39.	3.4	3
345	Inflammation and Its Mediators. , 2016, , 14-32.e2.		3
346	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 1073-1081.	2.0	3
347	Evidence-based Urology: Surrogate Endpoints – Pro. European Urology Focus, 2021, 7, 1217-1218.	3.1	3
348	Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. Clinical and Experimental Rheumatology, 2010, 28, 424-33.	0.8	3
349	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. Clinical Genitourinary Cancer, 2021, , .	1.9	3
350	Notice of redundant publication: Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 2013, 11, 2.	2.1	2
351	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2‥ear Results From the TENDER Trial. Arthritis and Rheumatology, 2014, 66, S96.	5.6	2
352	Digging deeper for greater precision and more impact in JIA. Nature Reviews Rheumatology, 2015, 11, 70-72.	8.0	2
353	Editorial comment to: Ileal versus sigmoid neobladder as bladder substitute after radical cystectomy for bladder cancer: A meta-analysis. International Journal of Surgery, 2017, 37, 13-14.	2.7	2
354	Re: Serra-Aracil et al.: The Place of Transanal Endoscopic Surgery in the Treatment of Rectourethral Fistula (Urology 2018;111:139-144). Urology, 2018, 115, 193-194.	1.0	2
355	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	3.0	2
356	"To Randomize, or Not to Randomize, That is the Question― Arthritis and Rheumatology, 2021, 73, 1776-1779.	5.6	2
357	Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. Rheumatology, 2022, 61, 2088-2094.	1.9	2
358	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancerâ€"Current State and Future Perspectives. Cancers, 2022, 14, 147.	3.7	2
359	IMMUNOLOGY AND RHEUMATIC DISEASES. , 2011, , 16-52.		1
360	The growth of Pediatric Rheumatology: Pediatric Rheumatology European Society and the impact factor. Pediatric Rheumatology, 2012, 10, 19.	2.1	1

#	Article	IF	CITATIONS
361	Strain Modal Testing with Fiber Bragg Grating Sensors of Composite Components for Automotive Applications. , 2021, , .		1
362	Estimation of the braking torque for MotoGP class motorcycles with carbon braking systems through machine learning algorithms. , 2021, , .		1
363	Multibody Models and Simulations to Assess the Stability of Counterbalance Forklift Trucks. Computational Methods in Applied Sciences (Springer), 2020, , 526-533.	0.3	1
364	Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. Clinical Genitourinary Cancer, 2022, 20, 389.e1-389.e7.	1.9	1
365	Acute kidney injury and functional outcomes after partial nephrectomy. International Journal of Urology, 2022, 29, 1243-1244.	1.0	1
366	Maladie de Still de l'enfant, évolution conceptuelle et thérapeutique. Revue Du Rhumatisme Monographies, 2012, 79, 3-6.	0.0	0
367	ls it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	O
368	A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment. Arthritis and Rheumatology, 2014, 66, S218-S219.	5.6	0
369	Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	O
370	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. Pediatric Rheumatology, 2014, 12, .	2.1	0
371	Static Balancing of a Parallel Kinematics Machine With Linear-Delta Architecture. , 2014, , .		O
372	Genetic association with articular damage in patients with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 2014, 12, .	2.1	0
373	The PRINTO juvenile dermatomyositis trial – Authors' reply. Lancet, The, 2016, 387, 2601.	13.7	O
374	Autoinflammatory syndromes: rare diseases with important implications in quality of life. Revista Brasileira De Reumatologia, 2016, 56, 1.	0.7	0
375	Reviewer acknowledgement 2015. Pediatric Rheumatology, 2016, 14, .	2.1	O
376	Resolution of pericardial constriction with anakinra; possible role of C reactive protein. International Journal of Cardiology, 2017, 234, 150.	1.7	0
377	SAT0024â€TRANSCRIPTOMIC PROFILING OF THE MICROENVIRONMENT DRIVEN RE-SHAPING OF PATHOGENIC CIRCULATORY AND SYNOVIAL HLA-DR+ CD4 T SUBSETS IN ACTIVE JUVENILE IDIOPATHIC ARTHRITIC PATIENTS. , 2019, , .		O
378	THU0517â€THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE ON ENROLLMENT. , 2019, , .		0

#	Article	IF	CITATIONS
379	OP0258â€LESSON FROM EUROFEVER REGISTRY AFTER THE FIRST TEN YEARS OF ENROLLMENT. , 2019, , .		O
380	THU0516â€LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
381	Re: Mathieu Rouanne, Dean F. Bajorin, Raquibul Hannan, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol 2020;3:728–38. European Urology Oncology, 2021, 4, 336.	5.4	0
382	Monogenic Autoinflammatory Syndromes. , 2009, , 33-49.		0
383	Overview of Juvenile Idiopathic Arthritis. , 2017, , 201-218.		0
384	Assessment of Wall Vibrations in the Long Pipe Facility at CICLOPE. Springer Proceedings in Physics, 2019, , 203-208.	0.2	0
385	Static Balancing of an Exechon-Like Parallel Mechanism. Lecture Notes in Mechanical Engineering, 2020, , 310-321.	0.4	0
386	Tofacitinib for juvenile idiopathic arthritis – Authors' reply. Lancet, The, 2022, 399, 1866.	13.7	0